Positive outcomes. Positive patient stories.
At Paratek, solutions are provided that enable positive outcomes and lead to positive patient stories. Paratek Pharmaceuticals is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments.
We focus on drugs that target infectious disease and other difficult to treat conditions.
Today, we have a particularly promising antibiotic called Omadacycline for serious community acquired infections where resistance is of concern.
Four core elements serve as the foundation upon which our brand is built. They guide how we communicate, how we act and the experiences we create for our stakeholders.
Paratek Pharmaceuticals is built on 4 values
We have a disciplined team with proven capabilities to develop and commercialize new treatment solutions for complex medical solutions.
We have unwavering passion for bringing effective solutions to patients, persevering through obstacles and building momentum to help people, empower physicians, and generate returns for investors.
We use the highest caliber research and development processes to harness the power of tetracycline-based chemistry, innovating to develop new compounds for a multitude of indications.
We are advancing science, working together to develop new compounds, and partnering with others to bring high impact solutions to physicians and openly sharing our progress and perspectives.
Everybody has a story about their healthcare. Many are stories of healing – the kind of stories we work towards everyday. Yet some have unhappier endings, poor outcomes; whether it’s an unsuccessful treatment, a serious side effect or a life threatening complication, these might have been avoided. The smallest decisions tip the scales. With the right drugs, the right knowledge and the right people, we can transform those everyday decisions into everyday triumphs.
In the end, data isn’t remembered - stories are. Physicians want their patients to have the best stories possible.
To empower physicians with the tools they need to create better stories. We’re on a mission to help turn every day decisions into everyday triumphs for patients with diseases that are not responsive to current treatments.
At Paratek, we provide solutions that enable positive outcomes and lead to positive patient stories. Read what our employees have to say about working to keep this promise.
We all have an opportunity to make a positive impact with the advancement of Omadacycline. For me, and for the company, that’s very exciting.Joanne Tatem, Director of Project Management
We're stepping into a new stage for anti-infectives. The passion of the leadership team and the board is truly palpable.Sarah Higgins, Controller
Paratek's team is made up of a variety of backgrounds within the pharmaceutical industry. The statistics below show the number of combined years of experience just within the Management and Executive teams.
Paratek's lead candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. In June 2015, we initiated a Phase 3 registration study in acute bacterial skin and skin structure infections to determine the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for CABP with omadacycline was initiated in November 2015.
Omadacycline is a new, once-daily, oral and IV, well-tolerated, broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), urinary tract infections (UTI), and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern.
We believe omadacycline will be used to treat patients in both the community and hospital setting. We have designed omadacycline to overcome many of the limitations of existing antibiotics. Omadacycline has a broad spectrum of activity, including activity against commonly resistant bacteria; it is dosed once daily and has both an oral and intravenous (IV) formulation. In clinical trials omadacycline has shown a favorable safety and tolerability profile.
As resistance to older antibiotic therapy continues to cause treatment failure we believe that omadacycline will become the primary antibiotic choice of physicians for use as an empiric monotherapy for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections and other serious community-acquired bacterial infections.
The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.
Our second Phase 3 product candidate, sarecycline, is a new, once-daily, oral tetracycline-derived compound for the potential treatment of acne and rosacea in the community setting. Sarecycline was designed to be a well-tolerated, once-daily, oral, narrow spectrum antibiotic with anti-inflammatory properties. Paratek has licensed the U.S. rights to Allergan for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Two identical Phase 3 registration studies were initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.